Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Application of Anticoagulation and Antiplatelet Therapy
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Application of Anticoagulation and Antiplatelet Therapy

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 10 February 2026 | Viewed by 485

Special Issue Editors

Prof. Dr. Rossella Marcucci

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, University of Florence, 50132 Florence, Italy
Interests: interventional cardiology; myocardial infarction; acute myocardial infarction; atherosclerosis; hypertension; heart failure; flow cytometry; cardiovascular medicine; atrial fibrillation; hemostasis and thrombosis
Special Issues, Collections and Topics in MDPI journals
Dr. Martina Berteotti

E-Mail Website
Guest Editor
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
Interests: interventional cardiology; myocardial infarction; acute myocardial infarction; atherosclerosis; hypertension; heart failure; flow cytometry; cardiovascular medicine; atrial fibrillation; hemostasis and thrombosis

Special Issue Information

Dear Colleagues,

This Special Issue delves into the different clinical settings in which we can apply antithrombotic therapies, both antiplatelet and anticoagulant.

We will explore the different clinical scenarios of atherothrombosis: coronary, cerebral, and peripheral artery diseases. Therefore, we will investigate the role and efficacy/safety ratio of these different pharmacological strategies.

In particular, we will focus on the clinical settings of highest thrombotic and bleeding risk, such as those with the contemporary presence of both antiplatelets and anticoagulants: atrial fibrillation plus acute coronary syndromes or ischemic stroke plus venous thromboembolism.

An emerging area is that of pharmacogenetic drugs, and we will evaluate the possible impact of the use of clopidogrel or warfarin.

Prof. Dr. Rossella Marcucci
Dr. Martina Berteotti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antiplatelets
  • anticoagulants
  • atherothrombosis
  • coronary artery disease
  • peripheral artery disease
  • cerebral artery disease
  • vitamin K antagonists
  • direct oral anticoagulants
  • clopidogrel
  • aspirin
  • ticagrelor
  • prasugrel

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 694 KB  
Article
Ischaemic Stroke in Patients with Known Atrial Fibrillation: A Snapshot from a Large University Hospital Experience
by Giulia Domna Scrima, Cristina Sarti, Giovanni Pracucci, Rita Nistri, Costanza Maria Rapillo, Benedetta Piccardi, Miroslava Stolcova, Francesca Ristalli, Alessio Mattesini, Carlo Nozzoli, Alessandro Morettini, Alberto Moggi Pignone, Patrizia Nencini, Carlo Di Mario, Rossella Marcucci and Francesco Meucci
J. Clin. Med. 2025, 14(17), 6012; https://doi.org/10.3390/jcm14176012 - 25 Aug 2025
Viewed by 286
Abstract
Objectives: Atrial fibrillation (AF) is associated with high risk of ischaemic stroke (IS). Oral anticoagulant therapy (OAT) is the standard of care for stroke prevention, even though its management remains challenging in clinical practice. An emerging problem is embolic events occurring on [...] Read more.
Objectives: Atrial fibrillation (AF) is associated with high risk of ischaemic stroke (IS). Oral anticoagulant therapy (OAT) is the standard of care for stroke prevention, even though its management remains challenging in clinical practice. An emerging problem is embolic events occurring on adequately conducted OAT, the so-called resistant stroke (RS). We aimed to describe pre-stroke prevention therapy, management on hospital discharge, and therapy at follow-up in all patients with AF hospitalized for IS and in the RS subgroup. Methods: We conducted a retrospective monocentric study of patients with known AF hospitalized for an IS. A subgroup with RS was identified. We recorded information on prevention therapy at home, recommended therapy at discharge, and data on outcome and prevention therapy at follow-up. Results: We identified 226 patients, 61% females, median age 84.04 years. Preventive therapy at home was performed in 121 (53.5%) (119 OAT and 2 Left Atrial Appendage Occlusion). At hospital discharge OAT was prescribed to 78.2% of patients. RS was diagnosed in 33 patients whose management at discharge was: same OAT in 12, shift to another Direct Oral Anticoauglant (DOAC) in 5, from DOAC to Vitamin K Antagonist (VKA) and vice versa in 11, non-specified OAT in 4. At final, follow-up of 208 days (range 85–443) 23.3% (34/146) did not assume OAT. OAT was significantly associated with survival probability (p < 0.001). Conclusions: Our findings confirm a scarce adoption of guidelines for AF-related embolic events, even in the absence of absolute contraindication to OAT. RS remains an underexplored clinical entity with empirical management, highlighting the need for targeted research and tailored therapeutic strategies. Full article
(This article belongs to the Special Issue Application of Anticoagulation and Antiplatelet Therapy)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop